Holen Sie sich die Stockscreener-App
13.59
3.27%
0.43
Handel nachbörslich:
13.59
Schlusskurs vom Vortag:
$13.16
Offen:
$13.17
24-Stunden-Volumen:
342.00K
Relative Volume:
0.29
Marktkapitalisierung:
$684.12M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-156.39M
KGV:
-3.6829
EPS:
-3.69
Netto-Cashflow:
$-123.06M
1W Leistung:
+5.27%
1M Leistung:
-6.79%
6M Leistung:
+27.13%
1J Leistung:
+7.18%
1-Tages-Spanne:
$13.12
$13.62
1-Wochen-Bereich:
$12.68
$13.65
52-Wochen-Spanne:
$7.30
$16.32
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Firmenname
Kalvista Pharmaceuticals Inc
Sektor
Branche
Telefon
(857) 999-0075
Adresse
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Vergleichen Sie KALV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
13.59 | 662.47M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-31 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
| 2024-12-18 | Eingeleitet | BofA Securities | Buy |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-29 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-20 | Eingeleitet | Needham | Buy |
| 2018-10-30 | Eingeleitet | Jefferies | Buy |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-31 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Kalvista Pharmaceuticals Inc Aktie (KALV) Neueste Nachrichten
KalVista Pharmaceuticals Inc. stock volume spike explainedJuly 2025 EndofMonth & Free Growth Oriented Trading Recommendations - Newser
Can technical indicators confirm KalVista Pharmaceuticals Inc.’s reversalJuly 2025 Update & Low Drawdown Trading Techniques - Newser
Price action breakdown for KalVista Pharmaceuticals Inc.2025 Macro Impact & AI Driven Stock Movement Reports - Newser
Real time social sentiment graph for KalVista Pharmaceuticals Inc.July 2025 Pullbacks & Weekly High Return Opportunities - Newser
KalVista Pharmaceuticals (KALV): Assessing the Technical Bull Case Amid Mixed Short-Term Signals - AInvest
KalVista Pharmaceuticals Stock Sees RS Rating Rise To 82 - Investor's Business Daily
Is KalVista Pharmaceuticals Inc. showing signs of accumulationDip Buying & Smart Allocation Stock Reports - Newser
What’s the recovery path for long term holders of KalVista Pharmaceuticals Inc.July 2025 Short Interest & AI Powered Market Entry Strategies - Newser
How institutional ownership impacts KalVista Pharmaceuticals Inc. stockJuly 2025 Patterns & Reliable Volume Spike Alerts - Newser
Can volume confirm reversal in KalVista Pharmaceuticals Inc.Trade Ideas & Risk Controlled Swing Trade Alerts - Newser
KalVista Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2025 - The Globe and Mail
Forecasting KalVista Pharmaceuticals Inc. price range with options dataQuarterly Portfolio Report & AI Enhanced Trade Execution Alerts - Newser
Bollinger Bands Show Potential Breakout in KalVista Pharmaceuticals Inc.IPO Watch & Intraday High Probability Setup Alerts - beatles.ru
Stocks To Watch: KalVista Pharmaceuticals Sees RS Rating Rise To 82 - Investor's Business Daily
Is KalVista Pharmaceuticals Inc. reversing from oversold territoryQuarterly Trade Summary & Risk Managed Investment Entry Signals - Newser
How to build a dashboard for KalVista Pharmaceuticals Inc. stockRate Cut & Weekly Breakout Watchlists - Newser
KalVista Pharmaceuticals Executives Sell Shares at $13.42/Share. - AInvest
Sentiment analysis tools applied to KalVista Pharmaceuticals IncJuly 2025 Update & Short-Term Trading Opportunity Alerts - Newser
KalVista Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
Sentiment analysis tools applied to KalVista Pharmaceuticals Inc.Rate Cut & Community Trade Idea Sharing - Newser
Analyzing recovery setups for KalVista Pharmaceuticals Inc. investors2025 Bull vs Bear & Safe Capital Growth Tips - Newser
How high can KalVista Pharmaceuticals Inc. stock goCEO Change & Long-Term Safe Investment Plans - Newser
Is KalVista Pharmaceuticals Inc. still worth holding after the dipEntry Point & Low Drawdown Trading Strategies - Newser
Measuring KalVista Pharmaceuticals Inc.’s beta against major indicesWeekly Stock Recap & Precise Entry and Exit Recommendations - Newser
KalVista Pharmaceuticals Inc. At Decision Level — Rebound or Resistance getLinesFromResByArray error: size == 0 - metrotimes.co.kr
Is this a good reentry point in KalVista Pharmaceuticals Inc.Weekly Gains Report & Risk Adjusted Buy/Sell Alerts - Newser
Is KalVista Pharmaceuticals Inc. forming a reversal pattern2025 Top Decliners & Technical Confirmation Trade Alerts - Newser
Hereditary Angioedema Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies - The Globe and Mail
Using economic indicators to assess KalVista Pharmaceuticals Inc. potentialJuly 2025 WrapUp & Fast Gain Swing Alerts - Newser
How to use Fibonacci retracement on KalVista Pharmaceuticals Inc.Rate Cut & Daily Profit Maximizing Trade Tips - Newser
Can KalVista Pharmaceuticals Inc. keep up with sector leadersWeekly Trade Recap & AI Enhanced Trade Execution Alerts - theviewers.co.kr
Can KalVista Pharmaceuticals Inc. maintain sales growthFed Meeting & High Accuracy Swing Trade Signals - theviewers.co.kr
What analysts say about KalVista Pharmaceuticals Inc. stock2025 Biggest Moves & Fast Moving Stock Trade Plans - theviewers.co.kr
Is KalVista Pharmaceuticals Inc. meeting your algorithmic filter criteriaQuarterly Trade Summary & Daily Entry Point Alerts - Newser
Can KalVista Pharmaceuticals Inc. deliver consistent dividends2025 Market Sentiment & Growth-Oriented Investment Plans - theviewers.co.kr
What is KalVista Pharmaceuticals Inc. s 5 year growth outlookM&A Rumor & Short-Term Swing Trade Alerts - theviewers.co.kr
KalVista Pharmaceuticals Inc. At Decision Level — Rebound or Resistance2025 Bull vs Bear & Weekly High Conviction Ideas - classian.co.kr
Institutional scanner results for KalVista Pharmaceuticals Inc.Weekly Trading Summary & Community Driven Trade Alerts - Newser
Applying Elliott Wave Theory to KalVista Pharmaceuticals Inc.Options Play & Free Expert Verified Stock Movement Alerts - Newser
KalVista Pharmaceuticals Announces 2026 Annual Meeting of Stockholders - AInvest
Momentum Traders Eye KalVista Pharmaceuticals Inc. for Quick BounceBull Run & Low Risk High Win Rate Stock Picks - beatles.ru
KalVista Pharmaceuticals sets June 2026 date for next annual stockholder meeting - Investing.com
KalVista Pharmaceuticals Updates Stockholder Meeting Schedule - TipRanks
Yea Christopher, KalVista Pharmaceuticals chief development officer, sells $34k in stock - Investing.com
KalVista Pharmaceuticals Executives Sell Shares at $13.19/Share on August 18, 2025. - AInvest
Kalvista pharma CMO Audhya sells $38k in shares - Investing.com
Intraday pattern recognizer results for KalVista Pharmaceuticals Inc.July 2025 Retail & Accurate Trade Setup Notifications - Newser
Does KalVista Pharmaceuticals Inc. stock pay reliable dividendsWeekly Trading Summary & Stock Portfolio Risk Control - Newser
KalVista Pharmaceuticals Inc. stock trend outlook and recovery path2025 Volume Leaders & Technical Analysis for Trade Confirmation - Newser
Will KalVista Pharmaceuticals Inc. benefit from macro trendsWeekly Stock Report & AI Enhanced Trade Execution Alerts - Newser
Does KalVista Pharmaceuticals Inc. qualify in momentum factor screening2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - Newser
Finanzdaten der Kalvista Pharmaceuticals Inc-Aktie (KALV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
8.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):